Rheumatoid Arthritis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults between 18 and 65 years old (inclusive) at the screening stage, of any gender, who weigh at least 35 kg.
• People who have been diagnosed with rheumatoid arthritis according to recognised 2010 classification standards.
• People whose rheumatoid arthritis is currently active and showing moderate-to-high levels of disease activity, despite receiving treatment.
• People taking standard anti-inflammatory or pain medications, provided the dose has been stable for at least 2 weeks before the first study dose and stays unchanged throughout the trial.
• People taking oral steroid medications, provided they have been on them for at least 4 weeks, at a stable and relatively low dose, for at least 4 weeks before the first study dose, and the dose stays unchanged throughout the trial.
• People taking certain disease-modifying medications (specifically methotrexate or leflunomide, within defined dose limits), provided they have been on them for at least 8 weeks, with the dose stable for at least 4 weeks before the first study dose, and unchanged throughout the trial.
• Women who could potentially become pregnant must have a negative pregnancy test at the screening stage.
• Women who could potentially become pregnant, and men who have not had a vasectomy, must use effective contraception from signing consent until 3 months after the last dose.
• People who are willing and able to follow the trial's requirements and schedule.
• People who are willing to give written informed consent and understand what the trial involves.

Who may not be able to join:

• People currently receiving biologic therapy (a specific type of medication used for immune conditions).
• People who have other inflammatory joint diseases or connective tissue diseases beyond rheumatoid arthritis.
• People with significant bone marrow problems, or seriously low levels of red blood cells, white blood cells, or platelets, where this is not caused by active rheumatoid arthritis.
• People who have had a persistent or serious infection within the 3 months before enrolling.
• People with uncontrolled high blood pressure, uncontrolled diabetes, unstable heart disease, active inflammatory bowel disease, active stomach ulcers, a terminal illness, or any other condition the trial doctor considers too risky for participation.
• People with serious heart, liver, neurological, hormonal, or other major health conditions that could interfere with the trial or its results.
• People with severely low protein levels in the blood (for example, due to serious liver disease or a kidney condition called nephrotic syndrome).
• People with moderate or severe kidney impairment, based on a specific blood test result (confirm with trial site).
• People with a recent or significant history of drug or alcohol misuse.
• People with impaired liver function, or persistently elevated liver enzyme levels above a certain threshold.
• People who are pregnant.
• People who are breastfeeding.
• People with a serious immune deficiency (either from birth or acquired), a history of cancer or lymphoma-related disorders, or those who have previously undergone total lymphoid irradiation (a type of radiation treatment).
• People who are known to be HIV-positive.
• People with known positive test results for hepatitis B or hepatitis C.
• People already enrolled in another clinical trial involving an investigational drug or device, or any other medical research study.
• People who have needed antibiotic or antimicrobial treatment for any active infection in the 28 days before the first study dose.
• People whose body mass index (BMI) is below 18.5 or above 30 (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.